Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...